Article Complete
AIM
Haleon to Invest ₹2,000 Crore in First India Manufacturing Facility in Madhya Pradesh
Haleon to Invest ₹2,000 Crore in First India Manufacturing Facility in Madhya Pradesh

Haleon to Invest ₹2,000 Crore in First India Manufacturing Facility in Madhya Pradesh

The site is expected to generate up to 500 direct jobs, along with indirect employment opportunities.

Published Updated

Key takeaways

  • Haleon is investing ₹2,000 crore to establish its first manufacturing facility in India.
  • The new facility in Madhya Pradesh is expected to create around 500 direct jobs and additional indirect employment.
  • The investment aligns with the government's 'Make in India' initiative, enhancing domestic manufacturing capacity.
  • Haleon aims to expand access to health products for over 300 million consumers in India.
  • The facility will strengthen Haleon's supply chain and support its growth strategy in Asia.
5 min

Haleon has announced an investment of approximately ₹2,000 crore to establish its first manufacturing facility in India, marking a significant expansion of its presence in the country’s fast-growing consumer health market. 

The greenfield facility will be set up at Pithampur in Madhya Pradesh and is expected to strengthen the company’s supply chain, boost exports, and support its long-term growth strategy in India and Asia.

Spread across more than 40 acres in the Smart Industrial Park, the facility is aligned with the government’s ‘Make in India’ vision and is designed to enhance domestic manufacturing capacity while improving export competitiveness across wider Asia.

The site is expected to generate up to 500 direct jobs, along with indirect employment opportunities, and will focus on local talent development and supplier ecosystem integration.

Brian McNamara, CEO at Haleon, said, “India is a key strategic market for Haleon and an important driver of our long-term growth. This investment strengthens our local manufacturing footprint and expands our reach in one of the world’s fastest-growing consumer health markets. By increasing access to our trusted brands and building our capabilities on the ground, we are well positioned to capture the significant opportunities ahead. We aim to expand access to better everyday health for more than 300 million additional consumers in India. This will be key to achieving our broader ambition to reach one billion more consumers globally by 2030.”

The company said the facility will feature future-ready automated manufacturing systems based on Haleon’s global advanced blueprint and is expected to become operational by 2029–30.

It will primarily support the production of oral health products, including established brands such as Sensodyne, which has been part of India’s oral care landscape for over a decade.

Once operational, the plant will support both domestic consumption and exports, reinforcing India’s position as a key hub in Haleon’s global manufacturing and supply network.

Kedar Lele, CEO India and President, Haleon ISC, added, “India is central to Haleon’s growth ambitions, both in South Asia and globally. Our investment in this new site will bring us closer to consumers, strengthen access to our brands, and support sustainable long-term growth. As demand for trusted everyday health solutions continues to grow, this facility will enhance our ability to serve consumers across India and global markets, particularly in Oral Health, while reinforcing our commitment to making everyday health more accessible to millions.”



Membership

Stay ahead with AI insights.

Unlimited access to premium articles, exclusive analysis, and the stories shaping India's AI economy.

Subscribe now

AIM Americas

1190 Miraloma Way Suite P, Sunnyvale, CA 94085

AIM India

1st Floor, Sakti Statesman, Bellandur, Bengaluru – 560103

© 2026 AIM. All rights reserved.